Related Posts
- Hydroxyurea vs Ruxolitinib in ET
KEY TAKEAWAYS The P2 phase II and MOST trials aimed to compare platelet control and…
- Teclistamab Dosing and Response Sustainability in RRMM
KEY TAKEAWAYS The MajesTEC-1 phase I and II trials aimed to evaluate biweekly dosing of…
- 1217 Triggering immune response from within cancer cells
Background Even as adoptive cell immunotherapy exhibits great success against liquid cancers, solid tumors continue…